Sarcopenia is a multifactorial condition related to the loss of muscle mass and strength due to aging, eating habits, physical inactivity, or even caused by another disease. Affected individuals have a higher risk of falls and may be associated with heart disease, respiratory diseases, cognitive impairment, and consequently an increased risk of hospitalization, in addition to causing an economic impact due to the high cost of care during the stay in hospitals. The standardization of appropriate treatment for patients with sarcopenia that could help reduce pathology-related morbidity is necessary. For these reasons, this study aimed to perform a systematic review of the role of nutrition and drugs that could ameliorate the health and quality of life of sarcopenic patients and PRISMA guidelines were followed. Lifestyle interventions have shown a profound impact on sarcopenia treatment but using supplements and different drugs can also impact skeletal muscle maintenance. Creatine, leucine, branched-chain amino acids, omega 3, and vitamin D can show benefits. Although with controversial results, medications such as Metformin, GLP-1, losartan, statin, growth hormone, and dipeptidyl peptidase 4 inhibitors have also been considered and can alter the sarcopenic’s metabolic parameters, protect against cardiovascular diseases and outcomes, while protecting muscles.

Type 1 diabetes mellitus (T1DM) involves the destruction of pancreatic β-cells, requiring ongoing insulin therapy. A promising alternative for management is pancreatic islet transplantation, or the bioartificial pancreas. Here, we examine the primary implantation sites for the bioartificial pancreas, highlighting their anatomical, physical, and immunological characteristics in the context of T1DM treatment. Traditionally used for islet transplantation, the liver promotes metabolic efficiency due to portal drainage; however, it presents issues such as hypoxia and inflammatory responses. The omentum offers excellent vascularization but has limited capacity for subsequent transplants. The renal subcapsular space is advantageous when combined with kidney transplants; however, its use is limited due to low vascularization. The subcutaneous space is notable for its accessibility and lower invasiveness, although its poor vascularization poses significant challenges. These challenges can be mitigated with bioengineering strategies. The gastrointestinal submucosa provides easy access and good vascularization, which makes it a promising option for endoscopic approaches. Additionally, the intrapleural space, which remains underexplored, offers benefits such as increased oxygenation and reduced inflammatory response. Selecting the ideal site for bioartificial pancreas implantation should balance graft support, complication reduction, and surgical accessibility. Bioengineered devices and scaffolds can address the limitations of traditional sites and enhance T1DM management.

Since current therapies cannot regenerate lost myocardium or reverse adverse ventricular remodeling—major contributors to worldwide cardiovascular mortality—advanced biomaterials, particularly hydrogels, have emerged as promising therapeutic platforms. Among these, bacterial nanocellulose (BNC) has gained increasing attention due to its hydrated nanofibrillar architecture, high crystallinity, robust mechanical performance, and excellent water-retention capacity, features that closely resemble key aspects of the native extracellular matrix. These properties provide a favorable microenvironment for cell adhesion, survival, and tissue organization in cardiovascular applications. Preclinical evidence suggests that BNC-based cardiac constructs, including acellular patches and cell-laden systems, may reduce post-infarction ventricular dilation, promote angiogenesis, and improve cellular engraftment. In vascular tissue engineering, BNC has also been explored in small-diameter grafts, anisotropic hydrogel systems, and shape-memory conduits with encouraging hemocompatibility and functional durability. Functional modifications—including gelatin incorporation, oxidative surface treatments, peptide grafting, conductive polymers, and structural alignment strategies—further expand the biological and mechanical versatility of BNC-based systems. In addition, BNC-containing bioinks have demonstrated promising rheological behavior, printability, and cell compatibility for 3D bioprinting applications. Despite these advances, important challenges remain, including optimization of material functionalization, host integration, degradation control, vascularization, scalable manufacturing, and regulatory translation toward clinical application.

Liver cancer remains a significant global health challenge, with hepatocellular carcinoma (HCC) being the most prevalent form. Despite advancements in treatment, high recurrence rates and the limited efficacy of conventional therapies highlight the need for novel interventions. Cinobufagin (CB), a bufadienolide extracted from the parotid secretion of Bufo gargarizans and B. melanostictus, has emerged as a promising compound with multiple antitumor mechanisms. This comprehensive review assesses the current evidence regarding CB and its containing medicine, cinobufacini, in liver cancer models. Cinobufacini is a traditional Chinese medicine extract, whereas CB refers specifically to one of its active components. The pharmacodynamic actions of CB include induction of apoptosis, DNA damage, inhibition of proliferation and migration, and modulation of key oncogenic pathways such as PI3K/Akt/mTOR, Akt/ERK, and AURKA-mTOR-eIF4E. Additionally, CB disrupts tumor metabolism and induces oxidative stress. Preclinical studies, both in vitro and in vivo, demonstrate significant antitumor efficacy. However, concerns remain regarding CB’s toxicity profile at high doses. This review emphasizes the therapeutic potential of CB in HCC treatment and advocates for further translational research to optimize its clinical applicability, dosage, and safety.

The study aims to gather and synthesize scientific information related to olfactory dysfunctions caused by SARS-CoV-2 (COVID-19). This is an integrative literature review carried out from scientific journals published from August to December 2021. Original articles with systematic literature reviews, retrospective observational studies, prospective descriptive studies, case-control studies and meta-studies were included meta-analyses. It was concluded that symptoms related to olfactory dysfunctions caused by COVID-19 vary according to age, sex, genetics, stage of the disease and pre-existing comorbidities. The mechanism of action by the virus to promote sensory changes is still uncertain. The main evidence suggests viral dissemination through the olfactory cleft neuroepithelium, with consequent infiltration in the olfactory bulb or neural loss mechanism, with direct damage to the olfactory sensory neurons. Given the complexity of the infection caused by COVID-19 it is essential to continue thematic research, especially in relation to the new variants of SARS-CoV-2.

Current research shows that shift work is associated with partial sleep deprivation and changes in circadian rhythms. The desynchronisation of these rhythms leads to an imbalance in physiological functions, which in turn can lead to the development of pathological conditions. This study compared the sleep quality of night workers with that of day workers. The results were compared with urinary cortisol levels in day workers. Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI) questionnaire. The results showed poor sleep quality in the night worker group, as well as complaints of anxiety, depression and hypertension. The desynchronisation caused by shift work may have negative effects on the body's homeostasis. These findings point to the need for forms of discipline that can improve the general health of night workers.